Evaluation of advantages of whole-process pharmaceutical care in treatment of advanced non-small cell lung cancer with immune checkpoint inhibitors
Xu Jing
Wang Xue-qun
Hu Wen-yi
Abstract：Objective To analyze the advantages of whole-process pharmaceutical care in the treatment of advanced non-small cell lung cancer with immune checkpoint inhibitors. Methods A total of 72 patients with advanced non-small cell lung cancer ad-mitted to Yingtan 184 Hospital from January 2022 to January 2024 were selected as the research subjects to receive immune check-point inhibitor treatment. These patients were divided into the control group (n=36) and observation group (n=36) by computer group-ing method. The patients in the control group received the routine treatment and nursing while those in the intervention group received the integrated pharmaceutical care in addition to the regimen in the control group. The difference in therapeutic efficacy was compared between the two groups. Results The symptom remission time and hospitalization time were significantly shorter in the observation group than in the control ((3.18±2.15) d vs (4.72±2.54) d,(4.25±0.73) d vs (6.32±0.53) d,all P<0.05). The comfort score was sig-nificantly higher in the observation group than in the control ((91.42±2.19) scores vs (72.21±2.32) scores,P<0.05). The complication rate was 25.00％ (9/36) in the control group and 5.56％ (2/36) in the observation group and the difference was statistically significant (x2=5.258,P<0.05). Conclusion The application of whole-process pharmaceutical care in the treatment of advanced non-small cell lung cancer patients with immune checkpoint inhibitors has a definite effect since it can shorten the course of patients' disease,promote patients' rehabilitation,ensure medication safety and improve patients' comfort. Therefore,it is worthy of promotion.
Keywords：Immune checkpoint inhibitorWhole-process pharmaceutical careComplicationNon-small cell lung cancerDrug safety
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 858-861 )